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S U M M A R Y
Objective: To compare outcomes of treating complicated skin and skin structure infections (cSSSI) caused
by methicillin-resistant Staphylococcus aureus (MRSA) with linezolid versus vancomycin in diabetic and
non-diabetic patients.
Methods: We pooled data from three prospective clinical trials in which 1056 patients were randomized
to receive either linezolid (intravenous (IV) or oral) or vancomycin (IV) every 12 h, for 7–28 days.
Results: Diabetic (n = 349) and non-diabetic patients (n = 707) had comparable demographics and co-
morbidities. Clinical success rates were lower in diabetic than in non-diabetic patients (72.3% and 85.8%,
respectively). Overall, non-diabetic patients had a shorter adjusted mean length of stay (LOS) compared
with diabetic patients (8.2 and 10.7 days, respectively; p < 0.0001). Among diabetic patients, rates were
comparable with linezolid and vancomycin treatment for clinical success (74% and 71%, respectively) and
microbiological success (60% and 54%, respectively). Among non-diabetic patients, clinical and
microbiological success rates were higher in linezolid- than in vancomycin-treated patients (90% and
81%, respectively, and 78% and 65%, respectively). Rates of drug-related adverse events were comparable
in diabetic and non-diabetic patients and with linezolid and vancomycin treatment. Adjusted mean LOS
was shorter with linezolid than with vancomycin treatment in diabetic patients (9.5 and 11.7 days,
respectively; p = 0.03) and non-diabetic patients (7.6 and 8.9 days, respectively; p = 0.02).
Conclusions: Clinical success rateswere lower in diabetic than non-diabetic patients with cSSSI caused by
MRSA. Comparing linezolid and vancomycin, clinical and microbiological success rates were comparable
in diabetic patients, but were better for linezolid than for vancomycin in non-diabetic patients.
 2010 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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Complicated skin and skin structure infections (cSSSI) are
common in persons with diabetes1 and may be more difﬁcult to
treat than in those without diabetes. However, few studies have§ This study was presented in part as a poster at the 47th Annual Meeting of the
Infectious Diseases Society of America (IDSA), October 2009, Philadelphia,
Pennsylvania, USA (poster #877).
* Corresponding author. Tel.: +1 206 277 1640; fax: +1 206 764 2849.
E-mail address: balipsky@uw.edu (B.A. Lipsky).
1201-9712/$36.00 – see front matter  2010 Published by Elsevier Ltd on behalf of In
doi:10.1016/j.ijid.2010.10.003compared outcomes of these infections in diabetic and non-
diabetic populations. Staphylococcus aureus is consistently
reported as the most commonly isolated pathogen in cSSSI, as
well as in diabetic foot infections,1,2 and methicillin-resistant S.
aureus (MRSA) strains have been isolated more frequently in many
communities worldwide.1,3,4,5 Some, but not all, studies indicate
that compared with other pathogens, MRSA infections are
associated with lower infection cure rates, higher amputation
rates, and increased mortality.5,6,7,8,9,10 The standard therapy for
MRSA infections is vancomycin; however, because of limitations of
this agent, several new anti-MRSA antibiotics have been devel-
oped. Among these, only linezolid can be administered orally asternational Society for Infectious Diseases.
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including diabetic foot infections, can be treated on an outpatient
basis; for this situation an oral agent would be preferable.
Tocompare theefﬁcacyandsafetyof linezolidandvancomycin in
diabetic and non-diabetic patients with cSSSI caused by MRSA, we
conducted a pooled analysis of data from three randomized
controlled trials.11,12,13 Our secondary objective was to compare
clinical andmicrobiological success rates and length of stay (LOS) in
hospitalized patients with and without diabetes, who were treated
with one of these two antibiotics for culture-conﬁrmedMRSA cSSSI.
2. Patients and methods
2.1. Study design
We analyzed data from three prospective randomized, open-
label, multicenter, phase 3b/4 clinical studies that examined the
efﬁcacy and safety of linezolid and vancomycin in diabetic and non-
diabetic patients hospitalized for cSSSI (including foot infections),
culture-conﬁrmed to be caused byMRSA.11,12,13 The assessments of
outcome in the original studies were blinded. The methods and
overall results of the individual studies have been published in
detail.11,12,13 In brief, eligible adults who provided institutional
reviewboard-approved informed consentwere randomized in a 1:1
ratio to receive from 7 to 28 days (based on the judgment of the
investigator) of linezolid 600 mg every 12 h (either intravenous (IV)
or oral)11,12,13 or IV vancomycin (either 15 mg/kg every 12 h with
dosages adjusted for creatinine clearance13 or 1 g every 12 h11,12).
Investigators were given permission to adjust vancomycin dosages
according to normal standards of care. In either treatment group,
investigators were allowed to add treatment with aztreonam or
gentamicin for suspected or proven infection with Gram-negative
pathogens. Similarly, for coverage of obligate anaerobic pathogens,
the investigators could add metronidazole. The duration of
treatment with aztreonam, gentamicin and metronidazole was
determined by the investigator. Investigators did not allow patients
to receive any type of local antimicrobial therapy.
2.2. Patients
In each of the three trials we identiﬁed enrolled patients with a
diagnosis of diabetes mellitus based on their medical history and a
review of their medications (seeking evidence of use of insulin or
oral hypoglycemic agents). For each enrolled patient we also
obtained selected data from their medical history, physical
examination, vital signs, and baseline laboratory tests. Investigators
obtained skin or soft tissue specimens for culture by incision and
drainage (n = 281), ﬁne-needle aspiration (n = 125), tissue biopsy
(n = 76), tissuescraping(n = 67), tissuedebridement (n = 45),wound
swabs of purulent lesions (n = 424), or other (unspeciﬁed) methods
(n = 38). The study protocols disallowed culture specimens obtained
by a superﬁcial swab from a relatively dry lesionwith no purulence.
Investigators obtained other types of culture specimens (e.g., blood)
at baseline if they believed they were indicated. All specimens for
culture were sent to the local microbiology laboratory for a Gram
stained smear, aerobic and anaerobic cultures, and antibiotic
susceptibility testingof all recoveredpathogens.Amongthepatients
with diabetes, we speciﬁcally identiﬁed the subset with a diabetic
foot infection, as deﬁned by the Infectious Diseases Society of
America guidelines, i.e., purulence or at least two classical signs of
inﬂammation of any inframalleolar lesion.1
2.3. Safety and efﬁcacy evaluations
To examine the safety of treatment with the two antibiotic
agents we pooled data from patients in the intent-to-treat (ITT)populations, deﬁned as patients with a cSSSI caused by any
pathogen who received at least one dose of study medication
(either linezolid or vancomycin).
To examine the clinical and microbiological efﬁcacy of the
treatments, we pooled data from all patients in the modiﬁed ITT
(MITT) populations, deﬁned as patients in the ITT populations who
hadMRSA isolated as a causative pathogen at baseline.We assessed
efﬁcacy outcomes at the test-of-cure (TOC) visit, deﬁned as 6–28
days after the last dose of study drug. We compared clinical and
microbiological success rates in patients with and without diabetes
and by treatment with linezolid versus vancomycin.
We categorized clinical response at TOC in each study as one of
three categories: ‘clinical success’, deﬁned as resolution of all
clinical signs and symptoms of infection that were identiﬁed at
baseline; ‘failure’, deﬁned as persistence or progression of clinical
signs and symptoms of infection after receiving at least two days of
treatment or development of new clinical ﬁndings consistent with
active infection; or, ‘unknown’, deﬁned as extenuating circum-
stances that precluded any other classiﬁcation.
We categorized microbiological outcome at TOC as one of the
following: ‘documented eradication’, deﬁned by a repeat culture
from the original infection site with no MRSA isolated; ‘presumed
eradication’, deﬁned by having no culture data, but a clinical
outcome deﬁned as success; ‘documented persistence’, deﬁned as
a repeat positive culture for MRSA from the original infection site;
‘presumed persistence’, deﬁned as no culture data available, but
the clinical outcome was a failure; or ‘recurrence’, deﬁned by a
positive culture for MRSA from the original infection site at TOC
when a culture was negative at the end of treatment. We excluded
any patient who could not be classiﬁed from the efﬁcacy analyses.
A central laboratory provided the ﬁnal pathogen identiﬁcation and
determined susceptibility to study drugs by a broth microdilution
method according to the Clinical and Laboratory Standards
Institute guidelines.
2.4. Length of stay evaluation
We calculated LOS for patients in the MITT populations by the
number of days in the hospital from the date of ﬁrst dose of study
drug to the date of discharge, independent of route of administra-
tion of study drug. Prior to this analysis, we determined that for
patients who were hospitalized longer than the study period of 35
days, their LOS would be set to 35 days. We did this because the
observation period of the clinical trial design was 35 days, and
truncation enabled the analysis to be based on uniformly
monitored data for all groups in all trials. As a result of truncation,
the calculated mean LOS did not reﬂect the actual mean LOS, but
was used solely to compare groups. Patients were excluded from
this analysis if clinical outcome was unknown. Patients with
missing clinical outcomes were excluded from the LOS analysis to
maintain a uniform data analysis set consistent with the clinical
portion of the ad hoc analysis. In the one study in which
hospitalization was not required, LOS was set to 0 when patients
were not hospitalized.12
2.5. Statistical analysis
We conducted all analyses on ﬁnal locked databases employing
the Statistical Analysis System (SAS Institute, Cary, NC, USA) and
used the Chi-square test or Fisher’s exact test to assess the
association between treatment and categorical variables, and the F
statistic to assess the association between treatment or diabetes
category and continuous variables. To estimate the effect of study,
we constructed separate logistic regressionmodels for the diabetic
and the non-diabetic populations. A logistic regression model was
run that contained only indicator variables for treatment and
Table 1
Baseline characteristics of diabetic and non-diabetic patients
Diabetic Non-diabetic
LZD
(n=171)
VAN
(n=178)
Total
(n=349)
LZD
(n=356)
VAN
(n=351)
Total
(n=707)
Difference
(95% CI) (diabetic
vs. non-diabetic)
Age, years, mean (SD) 59.8 (14.6) 58.6 (16.0) 59.2 (15.3) 47.4 (18.8) 47.3 (18.6) 47.4 (18.7) 11.8 (9.5, 14.1)
Male, n (%) 103 (60.2) 101 (56.7) 204 (58.5) 213 (59.8) 229 (65.2) 442 (62.5) 4.0 (10.4, 2.2)
Female, n (%) 68 (39.8) 77 (43.3) 145 (41.5) 143 (40.2) 122 (34.8) 265 (37.5) 4.0 (2.2, 10.4)
Race, n (%)
White 127 (74.3) 133 (74.7) 260 (74.5) 257 (72.2) 234 (66.7) 491 (69.5) 5.1 (0.7, 10.8)
Black 23 (13.5) 23 (12.9) 46 (13.2) 53 (14.9) 61 (17.4) 114 (16.1) 2.9 (7.4, 1.5)
Asian 3 (1.8) 7 (3.9) 10 (2.9) 9 (2.5) 8 (2.3) 17 (2.4) 0.5 (1.6, 2.5)
Other 10 (5.8) 7 (3.9) 17 (4.9) 25 (7.0) 35 (10.0) 60 (8.5) 3.6 (6.7, 0.6)
Not listed 8 (4.7) 8 (4.5) 16 (4.6) 12 (3.4) 13 (3.7) 25 (3.5) 1.1 (1.5, 3.6)
Weight, kg, mean (SD) 93.9 (31.5) 90.3 (28.5) 92.1 (30.0) 80.8 (21.0) 79.9 (25.6) 80.3 (23.4) 11.7 (8.4, 15.0)
Treatment duration, days,
mean (SD)
12.7 (4.8) 12.0 (5.2) 12.3 (5.0) 11.7 (4.7) 9.9 (4.6) 10.8 (4.8) 1.5 (0.9, 2.2)
Mean (SD) VAN dose, mg/day - 1814.0 (724.1) N/A - 1950.8 (636.1) N/A 136.8 (287.5, 13.9)
Concomitant Gram-negative
coverage, n (%)
114 (66.7) 111 (62.4) 225 (64.5) 169 (47.5) 171 (48.7) 340 (48.1) 16.4 (10.2, 22.6)
Concomitant anaerobic
coverage, n (%)
80 (46.8) 67 (37.6) 147 (42.1) 112 (31.5) 119 (33.9) 231 (32.7) 9.4 (3.2, 15.7)
Diabetic medication, n (%)
Oral hypoglycemics 21 (12.3) 27 (15.2) 48 (13.8) 0 0 0 N/A
Insulin 83 (48.5) 70 (39.3) 153 (43.8) 0 0 0
Oral hypoglycemics + insulin 47 (27.5) 61 (34.3) 108 (30.9) 0 0 0
None 20 (11.7) 20 (11.2) 40 (11.5) 356 (100) 351 (100) 707 (100)
Baseline serum glucose level,
mg/dl, mean (SD)
178 (91.5) 188 (92.6) 183 (92.0) 106 (28.8) 105 (24.0) 105 (26.6) 77.9 (68.5, 87.4)
Baseline diagnosis, n (%)
Cellulitis 21 (12.3) 19 (10.7) 40 (11.5) 51 (14.3) 53 (15.1) 104 (14.7) 3.3 (7.5, 0.1)
Abscess 45 (26.3) 58 (32.6) 103 (29.5) 171 (48.0) 170 (48.4) 341 (48.2) 18.7 (24.8, 1.3)
Infected skin ulcer 58 (33.9) 47 (26.4) 105 (30.1) 31 (8.7) 27 (7.7) 58 (8.2) 21.9 (16.7, 27.1)
Infected surgical incision 37 (21.6) 39 (21.9) 76 (21.8) 71 (19.9) 66 (18.8) 137 (19.4) 2.4 (2.8, 7.6)
Other 10 (5.9) 15 (8.4) 25 (7.2) 32 (9.0) 35 (10.0) 67 (9.5) 2.3 (5.8, 11.5)
Co-morbidities, n (%)
Cardiac 68 (39.8) 68 (38.2) 136 (39.0) 71 (19.9) 58 (16.5) 129 (18.3) 20.7 (14.9, 26.6)
Hepatobiliary 1 (0.6) 3 (1.7) 4 (1.2) 6 (1.7) 6 (1.7) 12 (1.7) 0.6 (2.0, 0.9)
Oncologic 8 (4.7) 5 (2.8) 13 (3.7) 13 (3.7) 15 (4.3) 28 (4.0) 0.2, (2.7, 2.2)
Renal 46 (26.9) 48 (27.0) 94 (26.9) 36 (10.1) 27 (7.7) 63 (8.9) 18.0 (12.9, 23.1)
Vascular 95 (55.6) 128 (71.9) 223 (63.9) 114 (32.0) 97 (27.6) 211 (29.8) 34.1 (28.0, 40.1)
Route of initial treatment,
n (%)
Intravenous 88 (51.5) 178 (100) 266 (76.2) 196 (55.1) 351 (100) 547 (77.4) N/A
Oral 83 (48.5) 0 83 (23.8) 160 (44.9) 0 160 (22.6)
CI, conﬁdence interval; LZD, linezolid; N/A, not applicable; SD, standard deviation; VAN, vancomycin.
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Table 2
Isolated pathogens from diabetic and non-diabetic patients
Isolated pathogens, n (%) Diabetic patients Non-diabetic patients
LZD VAN LZD VAN
MRSA 119 (69.6) 124 (69.7) 285 (80.1) 294 (83.8)
MRSA + other Gram-positive 30 (17.5) 26 (14.6) 34 (9.6) 21 (6.0)
MRSA + Gram-negative 14 (8.2) 14 (7.9) 27 (7.6) 26 (7.4)
MRSA + other Gram-positive + Gram-negative 6 (3.5) 13 (7.3) 8 (2.2) 9 (2.6)
MRSA + anaerobes 2 (1.2) 1 (0.6) 2 (0.6) 1 (0.3)
LZD, linezolid; MRSA, methicillin-resistant Staphylococcus aureus; VAN, vancomycin.
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model that included variables for treatment as well as factors that
were imbalanced by treatment group at baseline.
To account for differences by study, we used the adjusted odds
ratio (OR) to compare clinical and microbiological success rates
between the two treatment groups, for diabetic and non-diabetic
patients separately and for the total population. We estimated 95%
conﬁdence intervals (CIs) for the adjusted OR and considered
intervals that excluded 1.00 as statistically signiﬁcant. For
categorical analyses we considered p < 0.05 as statistically
signiﬁcant. We made no statistical adjustment for multiple
comparisons.
While we excluded all outcomes classiﬁed as missing,
unknown, or indeterminate in the calculations, we present them
for information purposes. Patients with missing, unknown, or
indeterminate clinical outcomes were excluded from the LOS
analysis to maintain a uniform data analysis set with the clinical
portion of the ad hoc analysis. The number of MITT patients who
had clinical outcome missing, unknown, or indeterminate and
were therefore not included in any of the LOS analyses (which was
the same data set for clinical and microbiological analyses) were:
57 diabetic patients (linezolid 31 and vancomycin 26) and 138
non-diabetic patients (linezolid 62 and vancomycin 76).
The outcomes research analysis of LOS incorporated study as a
class variable using the same coding as used in the clinical and
microbiological analyses in order to adjust for study effect. LOSwas
assessed using analysis of covariance in a model that compared
treatment effect in the diabetic and non-diabetic patients
separately, as well as for the total population, adjusted for the
study effect. Least square (LS) means were used to evaluate the
treatment or diabetes status effect size.
3. Results
3.1. Patient characteristics
Combining the three studies, a total of 868 diabetic patients
received at least one dose of either linezolid (n = 451) or
vancomycin (n = 417), and a total of 1688 non-diabetic patients
received at least one dose of either linezolid (n = 841) or
vancomycin (n = 847). These patients combined constituted the
ITT population.
In the ITT population, MRSA was isolated on culture at baseline
in 349 (40.2%) of the diabetic patients, including 171 treated with
linezolid and 178 treated with vancomycin. Similarly, MRSA was
isolated on culture at baseline in 707 (41.9%) of the non-diabetic
patients, including 356 treated with linezolid and 351 treated with
vancomycin. These patients constituted the MITT population and
we have summarized their baseline characteristics in Table 1.
Diabetic patients in the linezolid and vancomycin treatment
groups were comparable with respect to the distribution of their
age, sex, race, weight, diabetic medications, baseline cSSSI
diagnosis, and co-morbidities (with the exception of vascular
disease, which was less common in the linezolid treatment group).Compared with non-diabetic patients, diabetic patients were:
older; heavier; more frequently had underlying cardiac, renal, and
vascular co-morbidities; presented more commonly with an
infected skin ulcer; and more often received additional Gram-
negative coverage. Approximately 90% of the diabetic patients
were receiving oral hypoglycemicmedications, an insulin-contain-
ing regimen, or both. In the pooled analyses of patients in theMITT
population who received linezolid, 49% of diabetic patients and
45% of non-diabetic patients received the drug by the oral route as
initial treatment. There was no signiﬁcant difference in the
vancomycin daily dosing between diabetic and non-diabetic
patients.
3.2. Microbiological characteristics
Table 2 summarizes the baseline pathogens isolated in theMITT
population with and without diabetes. MRSA was identiﬁed as the
sole pathogen less frequently in patients with diabetes than in
thosewithout diabetes. Mixed infectionswith other Gram-positive
andGram-negative pathogensweremore frequent in patientswith
diabetes. Anaerobeswere identiﬁed infrequently in both treatment
groups, regardless of diabetes status. Overall, there were no
signiﬁcant differences in distributions of baseline pathogens
between patients in the linezolid and vancomycin groups when
stratiﬁed by presence or absence of diabetes.
3.3. Efﬁcacy
Table 3 summarizes the clinical and microbiological outcomes
in theMITT population by patient diabetes status. Overall, the rates
of clinical success were lower for diabetic patients compared with
non-diabetic patients (72.3% and 85.8%, respectively; absolute
difference 13.5%; adjusted OR 0.4, 95% CI 0.3–0.6). In diabetic
patients, those treated with linezolid and vancomycin had similar
rates of clinical success (73.6% and 71.1%, respectively; absolute
difference 2.5%; adjusted OR 1.2, 95% CI 0.7–2.0) and microbiolog-
ical success (60.4% and 54.2%, respectively; absolute difference
6.2%; adjusted OR 1.3, 95% CI 0.8–2.0).
In a sensitivity analysis of the diabetic patients in the MITT
population in which all missing, unknown, and indeterminate
clinical outcomes were set to failure, linezolid was found to have a
clinical success rate comparable to vancomycin (59% vs. 60%; 95%
CI –11.7% to 8.6%) and linezolid was found to have a microbiolog-
ical success rate comparable to vancomycin (54% vs. 51%; 95% CI –
7.3% to 14.2%). In patients without diabetes, linezolid treatment
resulted in signiﬁcantly higher clinical success rates (90.1% and
81.1%, respectively; absolute difference 9.0%; adjusted OR 2.1, 95%
CI 1.3–3.5) and microbiological success rates (77.8% and 64.9%,
respectively; absolute difference 12.9%; adjusted OR 1.9, 95% CI
1.3–2.7) comparedwith vancomycin. In a sensitivity analysis of the
non-diabetic patients in the MITT population in which we set all
missing, unknown, and indeterminate clinical outcomes to failure,
treatment with linezolid compared to vancomycin had a signiﬁ-
cantly higher clinical success rate (74% vs. 62%; 95% CI 4.7–18.1%)
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sensitivity analysis that adjusted efﬁcacy outcomes for factors that
were imbalanced at baseline gave similar results.
3.4. Safety
Table 4 summarizes adverse events that occurred among
diabetic and non-diabetic patients in the ITT population. The
percentage of patients with 1 adverse event was nearly identical
in both treatment groups in the diabetic patients, and the rates
were higher than in non-diabetic patients. The trend was the same
in patients with 1 serious adverse event. The percentage of
patients with 1 drug-related adverse event was nearly identical
for those treatedwith linezolid and vancomycin. The percentage of
diabetic patients who discontinued study treatment due to an
adverse event was similar with linezolid and vancomycin therapy.
Table 5 lists the most commonly reported drug-related adverse
events (DRAE) by diabetes status and type of antibiotic therapy.
Among diabetic patients receiving linezolid, the most common
reported DRAEs were diarrhea (5%), nausea (5%), and vomiting
(2%), while the most commonly reported DRAEs among diabetic
patients receiving vancomycin were diarrhea (2%), nausea (2%),
kidney failure or impairment (2%), and IV catheter site complica-
tions (2%). Among non-diabetic patients, the most commonly
reported DRAEs for linezolid were diarrhea (5%), nausea (5%),
headache (2%), vomiting (2%), and anorexia (2%), and the most
commonly reported DRAEs for vancomycin were rash (5%), IV
catheter site complications (3%), and nausea (2%).
We compared changes in laboratory values from baseline in
patients in the ITT population (not shown). The percentages of
diabetic patients who developed thrombocytopenia or anemia
(deﬁned as values < 75% of the lower limit of normal) were 6% and
1%, respectively, with linezolid, and 1% and 1%, respectively, with
vancomycin. Among non-diabetic patients, the percentages with
thrombocytopenia and anemia were 3% and 1% with linezolid, and
1% and 1% with vancomycin, respectively.
3.5. Subset analysis of diabetic foot infections
A total of 97 patients (57 in the linezolid group and 40 in the
vancomycin group) met classiﬁcation criteria for a diabetic foot
infection and had a skin or soft tissue culture that yielded MRSA.
Baseline demographic and clinical characteristics of these patients
were similar to those of the cohort of diabetic patients with a non-
foot skin infection. For patients with a diabetic foot infection,
clinical success rates were 76% with linezolid and 73% with
vancomycin (adjusted OR 1.3, 95% CI 0.53.6), andmicrobiological
success rates were 60% in each group (adjusted OR 1.0, 95% CI
0.42.5).
3.6. Length of stay
There were 16 patients (ﬁve treated with linezolid and six with
vancomycin among diabetic patients; two treated with linezolid
and threewith vancomycin among non-diabetic patients) who had
a LOS greater than 35 days, but whowere assigned a LOS of 35 days
for analysis purposes.
Overall, non-diabetic patients had a shorter adjusted mean LOS
compared with diabetic patients (8.2 vs. 10.7 days, respectively;
p < 0.0001; adjusted median LOS 5.0 vs. 8.0 days; respectively;
p < 0.0001). Among diabetic patients, the adjusted mean LOS was
shorter in linezolid-treated patients than in vancomycin-treated
patients (9.5 vs. 11.7 days, respectively; p = 0.03; adjusted median
LOS 7.0 vs. 8.0 days, respectively; p = 0.03). Similarly, among non-
diabetic patients, the adjusted mean LOS was shorter in linezolid-
treated patients than in vancomycin-treated patients (7.6 vs. 8.9
Table 4
Safety outcomes among patients by diabetes status and type of antibiotic therapy
ITT populationa Diabetic patients Non-diabetic patients
LZD (n=451) VAN (n=417) LZD (n=841) VAN (n=847)
1 AE, n (%) 256 (57) 239 (57) 421 (50) 414 (49)
1 serious AE, n (%) 79 (18) 57 (14) 69 (8) 55 (7)
1 drug-related AE, n (%) 88 (20) 83 (20) 191 (23) 188 (22)
1 AE leading to study drug discontinuation, n (%) 26 (6) 19 (5) 21 (3) 40 (5)
AE, adverse event; cSSSI, complicated skin and skin structure infection; ITT, intent-to-treat; LZD, linezolid; VAN, vancomycin.
a ITT population was deﬁned as all patients with cSSSI who received at least one dose of study medication.
Table 5
Reported adverse events among patients by diabetes status and type of antibiotic therapy
Adverse events, n (%) Diabetic patients Non-diabetic patients
LZD (n=451) VAN (n=417) LZD (n=841) VAN (n=847)
Diarrhea 23 (5) 8 (2) 45 (5) 6 (1)
Headache 6 (1) 4 (1) 13 (2) 9 (1)
Nausea 22 (5) 9 (2) 45 (5) 17 (2)
Vomiting 8 (2) 5 (1) 13 (2) 4 (0.5)
Anorexia 2 (0.4) 2 (0.5) 14 (2) 3 (0.4)
Kidney failure or impairment 2 (0.4) 7 (2) 0 7 (1)
Rash 1 (0.2) 4 (1) 9 (1) 38 (5)
IV catheter site complications 1 (0.2) 7 (2) 6 (1) 22 (3)
IV, intravenous; LZD, linezolid; VAN, vancomycin.
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respectively; p = 0.02).
Because six patients (three on vancomycin and three on
linezolid) from one study12 did not require hospitalization, we
reran the LOS analyses excluding these patients. Non-diabetic
patients had a shorter adjusted mean LOS compared with diabetic
patients (8.2 vs. 10.8 days, respectively; p < 0.0001). Among
diabetic patients, the adjusted mean LOS was shorter in linezolid-
treated patients than in vancomycin-treated patients (9.6 vs. 11.8
days, respectively; p = 0.02). Similarly, among non-diabetic
patients, the adjusted mean LOS was shorter in linezolid-treated
patients than in vancomycin-treated patients (7.6 vs. 9.6 days,
respectively; p = 0.03).
4. Discussion
The availability of data from three randomized controlled trials
allowed us to explore the important question of whether outcomes
of treatment of cSSSI caused by MRSA were different in patients
with diabetes compared with non-diabetic patients. These data
also enabled us to compare the clinical and microbiological
outcomes of these infectionswhen treatedwith IV vancomycin and
either IV or oral linezolid. In this large group of patients we found
that both the clinical and microbiological success rates were
signiﬁcantly lower in diabetic patients than in non-diabetic
patients, despite the fact that diabetic patientsmore often received
the optional additional antibiotic coverage for Gram-negative
pathogens (diabetic patients 64% and non-diabetic patients 48%)
and for anaerobic pathogens (diabetic patients 42% and non-
diabetic patients 33%). While the clinical and microbiological
success rates for patients treated with vancomycin and linezolid
were similar for the patients with diabetes, they were signiﬁcantly
better for non-diabetic patients who were treated with linezolid
than with vancomycin. It is also noteworthy that in almost half of
enrolled patients randomized to linezolid therapy, investigators
elected to prescribe initial therapywith the drug orally, rather than
intravenously.
There are several possible explanations for the outcome
differences in diabetic versus non-diabetic patients. To beginwith, diabetes is associated with various immune defects,14,15
including decreased T-cell-mediated immunity and neutrophil
dysfunction.16 Furthermore, as noted in our study, people with
diabetes have a higher rate of co-morbidities, including cardiac
abnormalities, renal insufﬁciency, and peripheral vascular disease.
Many studies have shown that diabetic patients are prone to
peripheral arterial atherosclerotic disease, small-vessel dysfunc-
tion, and, perhaps, platelet dysfunction, each of which may result
in decreased blood ﬂow to peripheral tissues. This decreased
perfusion could lead to decreased drug penetration to infected
sites. Some studies have reported decreased tissue penetration of
both linezolid and vancomycin in patients with diabetes.17,18,19
The higher body weight of patients with diabetes, as noted in our
study, may result in lower relative doses of an antibiotic that is not
adjusted for body weight. Another factor we noted is that patients
with diabetes had more infected ulcers and fewer abscesses than
non-diabetic patients. The latter are generally easier to cure, since
surgical drainage is a major part of their treatment.
In this study, the percentage of patients with adverse events,
including those that were serious, was higher in diabetic than in
non-diabetic patients in both treatment groups. The overall safety
proﬁles of linezolid and vancomycin were similar by diabetes
status. The percentage of diabetic patients with adverse events,
including serious and drug-related, was comparable for the two
treatment groups. Thrombocytopenia was uncommon and oc-
curred most often in diabetic and non-diabetic patients treated
with linezolid. Renal failure or impairment and catheter-related
adverse events were observed more frequently in vancomycin-
treated patients.
The adjusted mean LOS for treating these cSSSI was approxi-
mately 2–3 days longer for patients with diabetes compared with
non-diabetic patients. This difference may be a result of the higher
failure rate of treatment or the increased rate of complications and
co-morbid diseases associated with diabetes. The adjusted mean
LOS was signiﬁcantly shorter among patients treated with
linezolid compared with vancomycin, regardless of their diabetes
status. This difference is likely because linezolid has an oral step-
down option, which may allow earlier patient discharge from the
hospital.
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retrospective pooled analyses. Simple pooling of patients from the
three trials could lead to underestimation of standard errors
because it ignores potential heterogeneity across studies (when
generalizing beyond these three studies); however, our analyses
were based on three prospective randomized clinical trials with
predetermined primary endpoints of clinical and microbiological
cure rates. The studies had a different mix of infection types, with
cellulitis more common in the earlier studies11,12 and abscesses
more prevalent in the more recent study.13 Vancomycin dosing
was different in the most recent study (15 mg/kg every 12 h)
compared with the other two (1 g every 12 h). We lacked data on
glycemic control for the diabetic patients, a potentially important
confounder, although 90% of patients were receiving a diabetes
medication and 40% to 50% were using insulin.
In summary, in this pooled analysis of three randomized
controlled trials of patientswith cSSSI caused byMRSA, clinical and
microbiological success was signiﬁcantly lower in patients with
diabetes compared with those without diabetes. Among patients
with diabetes, clinical and microbiological success rates were
comparable for diabetic patients treated with either linezolid or
vancomycin, but both were signiﬁcantly higher with linezolid
treatment among non-diabetic patients. LOS was shorter among
non-diabetic patients, and was statistically signiﬁcantly shorter
among both diabetic and non-diabetic patients who received
linezolid compared with vancomycin. Despite the limitations of
our study, this analysis provides useful data on the treatment of
cSSSI caused by MRSA by patient diabetes mellitus status.
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